Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older
• People who have been diagnosed with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to treatment, still has signs of active disease, and who have already received at least one prior treatment
• People who have been diagnosed with a type of blood cancer called non-Hodgkin lymphoma (NHL) that has come back, stopped responding to treatment, or where other treatments that might help are not suitable or cannot be tolerated
• People who have not received chemotherapy or antibody-based treatment for at least 7 days before starting the trial drugs (people with fast-growing disease may have received certain specific medications up to 24 hours before starting, confirm with trial site)
• People whose blood counts meet certain minimum levels — specifically, a neutrophil count of at least 500/mm³, hemoglobin of at least 60 g/L, and platelet count of at least 30,000/mm³
• People whose liver, kidneys, and other organs are functioning well enough to safely take part (confirm specific requirements with trial site)
• People whose general physical condition is rated 0, 1, or 2 on a standard medical scale, meaning they are able to carry out at least some daily activities (confirm with trial site)
• People who are able to understand what the study involves and who have signed a consent form agreeing to take part (a legal representative may sign on behalf of the patient if needed)

Who may not be able to join:

• People who have previously been treated with a type of drug called an MDM2 inhibitor
• People who have active, uncontrolled cancer that has spread to the brain or spinal cord
• People who currently need treatment to manage graft-versus-host disease, or who have taken certain immune-suppressing medications called calcineurin inhibitors within the past 4 weeks
• People who have other health conditions or illnesses that, in the opinion of the medical team running the trial, could put them at risk or affect the reliability of the trial results
• People who have taken certain medications that strongly affect how the body processes drugs (specifically strong CYP2C8 inhibitors, or moderate or strong CYP3A4 inhibitors or inducers) within 14 days or 7 half-lives before starting the trial, whichever period is longer (confirm with trial site which medications apply)

Important: Always verify eligibility with the trial site directly before applying.